WHY: NEW YORK, NY - 
(NewMediaWire) - September 19, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) between August 3, 2022 and November 2, 2022, both dates inclusive (the “Class Period”), of the important November 7, 2023 lead plaintiff deadline.
WHAT TO DO NEXT: To join the Tandem class action, go to https://rosenlegal.com/submit-form/?case_id=19024 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 7, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, “Defendants misled investors by creating the false impression that as between three factors – competition, pandemic-related complications, and inflation – inflation alone accounted for the company’s reduced sales projections … Alternatively, Defendants deliberately ignored the impact of [other factors] … on sales and revenue. In either event, Defendants misled investors by providing the public with a materially flawed impression of the Company’s sales and revenue position for the remainder of 2022.”
Further, the complaint alleges that “Defendants misled investors by creating the false impression that the impact of competitors’ products, such as Omnipod 5, was minimal or less than expected. … Defendants’ forecasting processes failed to adequately account for the potential impact of the release of Omnipod 5 and the impact of that product on the Company’s revenue. Alternatively, [Defendants misled investors] regarding the impact of Omnipod 5 on revenue. Further, Defendants misled investors by creating the false impression that the factors which led to the decreased sales guidance in August … had not been adequately controlled for and were, in fact, improving. Alternatively, Defendants deliberately misled investors when stating that the second half of 2022 had been adequately predicted. In either event, Defendants misled investors by providing the public with materially flawed impression of the Company’s sales and revenue position for the remainder of 2022.” When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Tandem class action, go to https://rosenlegal.com/submit-form/?case_id=19024 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com
View the original release on www.newmediawire.com
